Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. It operates through the Carragelose and Marinosolv segments. The Carragelose segment contains products with anti-viral properties target viral infections of the respiratory tract of different virus strains. The Marinosolv segment refers to the technology platform that increases the bioavailability of hardly soluble compounds for the treatment of sensitive tissues such as nose and eyes. The company was founded by Andreas Grassauer and Eva Prieschl-Grassauer in 2006 and is headquartered in Korneuburg, Austria.